Please assess the completion status of the following clinical trial:

Trial Title: Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 60 years and older with de novo AML and non-poor cytogenetic features.~* Patients with no unfavourable cytogenetic (based on GOELAMS-BGMT criteria)~* Performance status and Sorror score \< 3 .~* Signed and dated informed consent.~Exclusion Criteria:~* Acute promyelocytic leukemia.~* Patients with myeloproliferative syndromes prior to diagnosis of AML.~* Patients who previously had myelodysplastic syndrome.~* Positive serology for HIV.~* Patients with unfavourable cytogenetic~* Patients with an isolated medullary extra localization of their disease

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients will be treated by adding lomustine to chemotherapy
- 2 (Type: NO_INTERVENTION): Patients will be treated without adding lomustine to chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).